ArticleThe journal of headache and pain2016
Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets.
Article in The journal of headache and pain, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Hallmarks of primary headache: part 3 - cluster headache.The journal of headache and pain · 2025Review
- PACAP versus CGRP in migraine: From mouse models to clinical translation.Cephalalgia : an international journal of headache · 2025Review
- Article
- Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.Annals of clinical and translational neurology · 2024Review
- Cluster headache: an update on clinical features, epidemiology, pathophysiology, diagnosis, and treatment.Frontiers in pain research (Lausanne, Switzerland) · 2024Review
- Article
- Neuroimaging in the pre-ictal or premonitory phase of migraine: a narrative review.The journal of headache and pain · 2023Review
- Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides.International journal of molecular sciences · 2023Review
- Shared and independent roles of CGRP and PACAP in migraine pathophysiology.The journal of headache and pain · 2023Review
- Review
- Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms.The journal of headache and pain · 2022Article
- Antiseizure medication in early nervous system development. Ion channels and synaptic proteins as principal targets.Frontiers in pharmacology · 2022Review
- PACAP Induces Light Aversion in Mice by an Inheritable Mechanism Independent of CGRP.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Cluster headache pathophysiology - insights from current and emerging treatments.Nature reviews. Neurology · 2021Review
- Pituitary adenylate cyclase-activating polypeptide (PACAP) modulates dependence-induced alcohol drinking and anxiety-like behavior in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Role of the PACAP system of the extended amygdala in the acoustic startle response in rats.Neuropharmacology · 2019Article
- Perivascular neurotransmitters: Regulation of cerebral blood flow and role in primary headaches.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019Review
- PACAP and its role in primary headaches.The journal of headache and pain · 2018Review
- Parasympathetic Cholinergic and Neuropeptide Mechanisms of Migraine.Anesthesiology and pain medicine · 2017Review
- Puzzling Out Synaptic Vesicle 2 Family Members Functions.Frontiers in molecular neuroscience · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine and Cluster Headache (CH) are two primary headaches with severe disease burden. The disease expression and the mechanisms involved are poorly known. In some attacks of migraine and in most attacks of CH, there is a release of vasoactive intestinal peptide (VIP) originating from parasympathetic cranial ganglia such as the sphenopalatine ganglion (SPG). Patients suffering from these diseases are often deprived of effective drugs. The aim of the study was to examine the localization of the botulinum toxin receptor element synaptic vesicle glycoprotein 2A (SV-2A) and the vesicular docking protein synaptosomal-associated protein 25 (SNAP25) in human and rat SPG. Additionally the expression of the neurotransmitters pituitary adenylate cyclase activating polypeptide (PACAP-38), nitric oxide synthase (nNOS), VIP and 5-hydroxttryptamine subtype receptors (5-HT1B,1D,1F) were examined.
methodsSPG from adult male rats and from humans, the later removed at autopsy, were prepared for immunohistochemistry using specific antibodies against neurotransmitters, 5-HT1B,1D,1F receptors, and botulinum toxin receptor elements.
resultsWe found that the selected neurotransmitters and 5-HT receptors were expressed in rat and human SPG. In addition, we found SV2-A and SNAP25 expression in both rat and human SPG. We report that all three 5-HT receptors studied occur in neurons and satellite glial cells (SGCs) of the SPG. 5-HT1B receptors were in addition found in the walls of intraganglionic blood vessels.
conclusionsRecent focus on the SPG has emphasized the role of parasympathetic mechanisms in the pathophysiology of mainly CH. The development of next generation's drugs and treatment of cranial parasympathetic symptoms, mediated through the SPG, can be modulated by treatment with BoNT-A and 5-HT receptor agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.